Safety considerations and data sources are crucial to consider when designing studies for rheumatology treatments, according to presenters at the 2022 ACR-FDA Summit.
American Medical Association House of Delegates Meets In-Person; ACR Successfully Advances New Policies
The ACR’s resolution addressing inappropriate Medicare Administrative Contractor policy processes was adopted, and two co-led resolutions on ARPA-H funding and saline shortages also passed the policy-making body.
PsA Trial Design Can Improve Patient Safety, Outcomes
For best safety and efficacy outcomes, trials in psoriatic arthritis should use active comparators and stricter remission criteria, with outcome measures that are important to patients.
Some Cannabis Products May Ease Chronic Pain, But Side Effects Are a Concern
NEW YORK (Reuters Health)—Oral synthetic cannabis products that have a high tetrahydrocannabinol (THC) to cannabidiol (CBD) ratio, as well as extracted cannabis products with comparable THC-to-CBD ratios, may provide moderate, short-term improvements in chronic pain, a large systematic review of relevant research suggests.1 However, these products are also associated with higher risks for side effects,…
Early Data on Novel MK2 Inhibitor to Treat Inflammatory Diseases Promising
In a small preliminary study, the novel MK2 inhibitor, CC-99677, was safe and well tolerated by healthy participants. With daily dosing, the agent sustained reductions of tumor necrosis factor alpha and other cytokines for 14 days.
Gene Profiling May Predict Treatment Response in Refractory Rheumatoid Arthritis
NEW YORK (Reuters Health)—In patients with rheumatoid arthritis (RA) refractory to treatment with rituximab or tocilizumab, genetic profiling of synovial biopsies predicted the lack of therapeutic response better than a model using only tissue pathology or clinical factors, researchers say.1 “We believe this study is a paradigm shift in precision medicine in RA,” Dr. Costantino…
Researchers Should Use ACR/EULAR Definition of RA Remission in Clinical Studies
Clinical trials in rheumatoid arthritis (RA) should use the new ACR/EULAR remission definition rather than the Disease Activity Score-28-CRP, which does not sufficiently reflect patient outcomes, according to an ACR/EULAR committee.
ACR Delegation Asks AMA to Address Issues Impacting Rheumatology
After two years of special virtual sessions, the AMA House of Delegates will reconvene in person June 10–15. ACR representatives will focus on Medicare physician payment system reform, national drug shortages, funding the new Advanced Research Projects Agency for Health and more.
In 2022, Advocacy 101 Returns to Washington, D.C.
ACR and ARP members converged on Capitol Hill in May to urge lawmakers to support legislation related to workforce expansion and patient access to care following training sessions presented by ACR staff dedicated to legislative affairs.
European Medicines Agency Committee Issues Positive Opinion for Secukinumab in Pediatric Arthritic Disease
In the E.U., secukinumab is edging closer to approval for use in pediatric patients with juvenile idiopathic arthritis (JIA), specifically those with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA). In May, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on expanding its indications.
- « Previous Page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- …
- 316
- Next Page »